Work for Anixa Biosciences, Inc.?

Claim Your Profile

Anixa Biosciences, Inc. Logo Image

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. Banner Image

About Anixa Biosciences, Inc.

1-10 Employees
Based in San Jose, California

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. Anixa's vaccine portfolio consists of a technology focused on the immunization against a "retired" protein, α-Lactalbumin, to prevent triple negative breast cancer (TNBC), the most lethal form of breast cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

NASDAQ (See More NASDAQ Companies)
Diagnostic Substances (See More Diagnostic Substances Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol